
|Articles|September 29, 2022
Achieving High Yield, Versatility, and Scalability for Adherent Cell Culture with Circulation/Perfusion Systems
Author(s)Corning Life Sciences
With the ever-growing demand for vaccines and advanced therapy products, cell culture platforms are challenged to provide cost-effective, high-yield production that can easily transition from process development through large-scale manufacturing. Ann Rossi Bilodeau, Ph.D. from Corning Life Sciences discusses what the Corning® CellCube® has to offer for the end user.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5